AbbVie Announces Positive Phase 3 Results for Lutikizumab in Hidradenitis Suppurativa

AbbVie reported positive topline results from its Phase 3 INTREPID trial for lutikizumab, demonstrating significant improvements in patients with hidradenitis suppurativa compared to a placebo. This achievement marks an important milestone in AbbVie's immunology pipeline. The company plans to present these findings to regulatory authorities and at upcoming medical congresses.